The expression of drug transporters and metabolizing enzymes is a primary determinant of drug disposition. Chimeric mice with humanized liver, including PXB mice, are an available model that is permissive to the in vivo infection of hepatitis C virus (HCV), thus being a promising tool for investigational studies in development of new antiviral molecules. To investigate the potential of HCV infection to alter the pharmacokinetics of small molecule antiviral therapeutic agents in PXB mice, we have comprehensively determined the mRNA expression profiles of human ATP-binding cassette (ABC) transporters, solute carrier (SLC) transporters, and cytochrome P450 (P450) enzymes in the livers of these mice under noninfected and HCV-infected conditions. Infection of PXB mice with HCV resulted in an increase in the mRNA expression levels of a series of interferon-stimulated genes in the liver. For the majority of genes involved in drug disposition, minor differences in the mRNA expression of ABC and SLC transporters as well as P450s between the noninfected and HCV-infected groups were observed. The exceptions were statistically significantly higher expression of multidrug resistance-associated protein 4 and organic anion-transporting polypeptide 2B1 and lower expression of organic cation transporter 1 and CYP2D6 in HCV-infected mice. Furthermore, the enzymatic activities of the major human P450s were, in general, comparable in the two experimental groups. These data suggest that the pharmacokinetic properties of small molecule antiviral therapies in HCV-infected PXB mice are likely to be similar to those in noninfected PXB mice. However, caution is needed in the translation of this relationship to HCV-infected patients as the PXB mouse model does not accurately reflect the pathology of patients with chronic HCV infection.
Introduction
Elimination of endogenous and exogenous substances is one of the most important physiological functions of the liver, which comprises the sinusoidal uptake from the blood circulation, intracellular phase I and phase II metabolism, and canalicular efflux of parent compound and/or metabolites into bile. Cumulative evidence suggests that members of the solute carrier (SLC) and ATP-binding cassette (ABC) transporters are expressed on either sinusoidal or canalicular membrane of the hepatocytes where they are responsible for the sinusoidal uptake and bile canalicular efflux of a diverse set of compounds (Chandra and Brouwer, 2004; Shitara et al., 2006; Dobson and Kell, 2008) . On the other hand, cytochrome P450 enzymes are localized to the endoplasmic reticulum of hepatocytes and are the major enzymes involved in phase I drug metabolism and bioactivation, accounting for approximately 75% of the oxidative metabolism of marketed drugs (Gonzalez, 1990; Rendic and Di Carlo, 1997) . Other enzymes such as glutathione transferase, UDP-glucuronosyltransferase, and sulfotransferase are involved in the conjugation of xenobiotics in phase II metabolism (Meyer, 1996; Williams et al., 2004) . The expression and function of these transporters and enzymes are important determinants of the physiological turnover of endogenous compounds and clearance of exogenous substances including clinically used drugs.
Hepatitis C virus (HCV) infects an estimated 170 million people worldwide, and its infection is a leading cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (World Health Organization, 1999) . Currently, the combination therapy of pegylated interferon (IFN) and ribavirin is the only approved treatment for HCV infection. However, this treatment regimen is only effective in ap-proximately 50% of all patients infected with HCV. A number of individuals with HCV infection are unable to achieve a sustained virological response with the current therapy, and many of them will progress to liver diseases resulting from chronic infection with HCV. Thus, the development of more efficient therapies against HCV is of high priority (Wakita, 2007) .
Several in vitro experimental models have been used to investigate the pathology of HCV as well as the efficacy of potential therapeutic compounds. These models include the use of individually cloned proteins of HCV (Littlejohn et al., 1998) , infection of primary culture human hepatocytes with HCV (Buck, 2008) , and in vitro HCV replicon systems in Huh-7 cells (Bartenschlager, 2005) . The HCV replicon systems are particularly useful in HCV research and drug discovery because they are both permissive to high-efficiency HCV replication and respond to antiviral compounds including IFN-␣ and ribavirin. However, several limitations exist with the use of replicon systems in the discovery and development of novel anti-HCV compounds. These include the cell culture-adaptive mutations of the HCV genome and the innate difference of Huh-7 cells, which are immortalized tumor cells, compared with hepatocytes.
Because of the strict tropism of HCV, only humans and higher primates, such as chimpanzees, have, until recently, been receptive to authentic HCV infection and the development of chronic liver disease due to HCV infection (Lanford et al., 2001; Kremsdorf and Brezillon, 2007) . However, use of chimpanzees is difficult from ethical and economical perspectives. The chimeric mouse with a humanized liver on the genetic background of urokinase plasminogen activator-transgenic severe combined immunodeficiency disorder (uPA/SCID) mice, designated as the PXB mouse, has been developed and characterized (Tateno et al., 2004) . The livers of these mice are near completely (Ͼ70%) replaced with human hepatocytes and maintain the hepatic expression of most human drug-metabolizing enzymes and transporters (Nishimura et al., 2005) . Subsequent studies have demonstrated that this mouse model is permissive to the infection of HCV in vivo and has potential utility in the discovery and development of new anti-HCV therapy (Umehara et al., 2006; Hiraga et al., 2007; Inoue et al., 2007) . However, one should note that HCV-infected PXB mice do not precisely mimic chronic HCV infection in humans because these mice lack the adaptive immune response and liver disease associated with HCV infection as a result of their genetic background (SCID).
Because the primary organ of HCV infection and its replication is the liver, it is of great importance to know the possible alterations in the hepatic expression and activity of pharmacokinetics-related genes, i.e., drug transporters and metabolizing enzymes, by HCV infection. The aim of the present study was thus to investigate the effect of HCV infection on the mRNA expression of human ABC and SLC transporters and cytochrome P450 enzymes in the livers of PXB mice. Furthermore, the enzymatic activities of major human cytochrome P450 enzymes were compared between noninfected and HCV-infected PXB mice.
Materials and Methods
Generation of PXB Mice. PXB mice were generated by transplanting 1.0 ϫ 10 6 human hepatocytes into the spleens of 2-to 3-week-old uPA/SCID mice under diethyl ether anesthesia as described previously (Tateno et al., 2004) . All PXB mice used in the present study were derived from the same donor human hepatocyte (BD87, male, 2-year-old white; BD Biosciences, San Jose, CA).
Inoculation of HCV to PXB Mice. The inoculum used in the present study was HCV genotype 1b (HCR6, accession no. AY045702), which was obtained from HCV-infected PXB mice at the third passage. The original inoculum was obtained from the serum of an HCV-positive patient. PXB mice with a human albumin concentration in the blood greater than 6.0 mg/ml were infected with HCV genotype 1b at 9 to 10 weeks of age by injecting the inoculum (1.0 ϫ 10 4 copies/mouse) to the retro-orbital sinus under diethyl ether anesthesia.
Quantification of Human Albumin Concentration and HCV Titer in the Serum. The concentration of human albumin in mouse blood was determined by latex agglutination immunonephelometry at 13 to 17 weeks of age. The replacement index is defined as the percentage of human hepatocyte repopulated in the host mouse liver and can be estimated from the blood human albumin value. RNA was extracted from the serum of PXB mice using a Sepa Gene RV-R RNA extraction system (Sanko Junyaku Co., Ltd., Ibaraki, Japan) according to the manufacturer's instructions, and the serum titer of HCV was determined by real-time quantitative PCR using TaqMan EZ RT-PCR Core Reagent and an ABI Prism 7500 sequence detector system as described previously (Takeuchi et al., 1999) .
RNA Isolation and TaqMan Gene Expression Assays. Body weight was measured, and the liver was harvested from each mouse at 17 to 19 weeks of age. Total RNA was isolated from liver specimens using TRIzol (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions and then treated with DNase I to remove contaminating genomic DNA. For cDNA synthesis, 80 ng of RNA was reverse-transcribed using a Transcriptor First Strand cDNA Synthesis Kit (Roche Applied Science, Indianapolis, IN) with random hexamer as the primer. The mRNA expression of human ABC transporters, SLC transporters, cytochrome P450 enzymes, and interferon-stimulated genes (ISGs) was quantified by TaqMan Gene Expression Assays on an ABI Prism 7900 system (Applied Biosystems, Foster City, CA) using LightCycler 480 Probe Master (Roche Applied Science) with primers and FAM-TAMRA or FAM-Iowa Black dual-labeled probes (Integrated DNA Technologies, Inc., Coralville, IA) that are specific for human genes. The protocol for PCR was as follows: 50°C for 2 min, 95°C for 10 min, and 40 cycles of 95°C for 15 s and 60°C for 1 min. The assay identification number or sequences of primers and probes used in the present study are listed in Table 1 . The specificities of primers and probes to human genes were confirmed by comparing the amplification from human or mouse liver cDNA. No specific amplification was observed when mouse liver cDNA was used as a PCR template for all genes tested (data not shown). HCV RNA content in the livers of PXB mice was also quantified by TaqMan Gene Expression Assays using a cocktail of three forward primers, one reverse primer, and two TaqMan probes (Table 1) as described previously (Cook et al., 2004) . The mRNA expression of each gene was quantified using the comparative C t method, and normalized by the mRNA expression of hGAPDH.
Preparation of Liver Microsomes and Determination of Activities of Cytochrome P450 Enzymes. The microsomal fractions were isolated from the livers of noninfected and HCV-infected PXB mice at 18 or 20 weeks of age as described previously and stored at Ϫ70°C until further use (Sugihara et al., 2001) . The activities of various P450s were determined in liver microsomes of PXB mice using selective substrates for the human P450 isoforms at appropriate concentrations (Table 2 ). In brief, 0.2 mg/ml microsomes were preincubated with substrate in 50 mM potassium phosphate buffer (pH 7.4) containing 5 mM MgCl 2 at 37°C for 5 min, and, subsequently, 2 mM NADPH was added to start the enzyme reaction. After the incubation at 37°C for 30 min (CYP1A2, CYP2C9, and CYP2C19), 15 min (CYP2D6), or 10 min (CYP3A4), the reaction was terminated by the addition of 150 l of acetonitrile containing 7-hydroxycoumarin as an internal standard to 100 l of incubation mixture. Samples were then centrifuged at 3000 rpm for 10 min at 4°C to precipitate the protein, and 10 l of supernatant was analyzed by liquid chromatography (LC)-tandem mass spectrometry (MS/MS) to quantify the formation of metabolite. For the detection of acetaminophen, the supernatant as well as standard curves were further diluted with 5 mM ammonium acetate to ensure that the signal of each analyte was within the linear range of LC-MS/MS analysis. All of the experiments were conducted in triplicate.
LC-MS/MS Analysis. LC-MS/MS was performed on a Shimadzu highperformance liquid chromatography system with two LC-10ADvp pumps and the SCL-10Avp controller (Shimadzu Scientific Instruments, Columbia, MD) and an ABI Sciex API 4000 (Applied Biosystems). Samples were separated on a Hypersil BDS C18 column (50 ϫ 2.1 mm, 5 m; Thermo Fisher Scientific, Waltham, MA) with mobile phase A (0.1% formic acid in 5 mM ammonium acetate) and B (0.1% formic acid in acetonitrile/methanol 50/50, v/v) at a flow rate of 0.4 ml/min. High-performance liquid chromatography gradient programs were as follows: for CYP1A2, CYP2C9, and CYP2C19 assays, 1) mobile phase B was maintained at 5% for 1.0 min, 2) increased linearly to 90% from 1.0 to 2.0 min and maintained to 3.0 min, and 3) brought back to the initial concentration linearly from 3.0 to 3.1 min for reequilibration, total run time 4.0 min; for CYP2D6 assay, 1) mobile phase B was maintained at 5% for 1.0 min, 2) increased linearly to 95% from 1.0 to 2.0 min and maintained to 4.0 min, and 3) brought back to the initial concentration linearly from 4.0 to 4.1 min for reequilibration, total run time 6.0 min; and for CYP3A4 assay, 1) mobile phase B was maintained at 5% for 1.0 min, 2) increased linearly to 95% from 1.0 to 2.0 min and maintained to 3.0 min, and 3) brought back to the initial concentration linearly from 3.0 to 3.1 min for reequilibration, total run time 4.0 min. The MS/MS parameters and linear range of standard curves (limit of detection to maximum concentration) are listed for each metabolite in Table 2 . Data were collected and processed using Sciex Analyst 1.4.2 data collection and integration software. Statistical Analysis. Statistical analysis was performed by Student's t test using GraphPad Prism (version 4). Asterisks represent significant differences ‫,ء(‬ P Ͻ 0.05, ‫,ءء‬ P Ͻ 0.01, and ‫,ءءء‬ P Ͻ 0.001, respectively) between noninfected and HCV-infected PXB mice.
Results
Human Albumin Concentration and HCV Titers in PXB Mice. Sex, human albumin concentration in the blood, body weight, serum HCV titers, and HCV RNA content in the liver are summarized in Table 3 for each mouse. The sex of PXB mice did not affect the activity of human cytochrome P450 enzymes derived from the human hepatocytes inside the host mouse liver (supplemental data). The average concentration of human albumin in the blood was not significantly different between noninfected and HCV-infected PXB mice. Accordingly, the replacement index of human hepatocytes estimated from the albumin concentration was similar between the two groups. Although body weight at the time of liver isolation was significantly higher in HCV-infected PXB mice than in noninfected mice for those used for the preparation of total liver RNA, the difference was not statistically significant in those used for the preparation of liver microsomes. Indeed, unpublished observations (C. Tateno) with different batches of HCV-infected mice suggested that HCV infection does not significantly affect the body weight of either male or female PXB mice. Serum HCV titers were determined in HCV-infected PXB mice, and HCV RNA content in the liver was measured in both noninfected and HCV-infected groups. A significant amount of HCV RNA was detected in both the serum and liver of HCV-infected mice, whereas HCV RNA was not detected in the liver of noninfected mice. These results confirmed that PXB mice were successfully infected by HCV.
Activation of Interferon-Signaling Pathways in HCV-Infected PXB Mice. Previous reports suggested that chronic infection with HCV is accompanied by the up-regulation of genes related to the interferon-signaling pathways in human patients (Smith et al., 2006) . To corroborate the relevance of our experimental model in PXB mice to clinical HCV infection, the mRNA expression of human ISGs observed to be activated in HCV-infected patients was quantified in the livers of noninfected and HCV-infected mice. Fourteen of 22 ISGs investigated exhibited a significant increase in mRNA expression in the livers of HCV-infected PXB mice compared with that in noninfected mice (Fig. 1) . The mRNA expression of MX2 was below the limit of detection in both groups. These results suggest that the interferon signaling pathways are activated by HCV infection in PXB mice, which is similar to what is observed in patients with chronic HCV infection.
mRNA Expression of Human ABC and SLC Transporters. The mRNA expression of major human hepatic ABC and SLC transporters was quantified in the livers of noninfected and HCV-infected PXB mice (Fig. 2) . A significant increase in mRNA expression was ob- 
EFFECT OF HCV INFECTION IN PXB MICE
at ASPET Journals on October 20, 2017 dmd.aspetjournals.org
Downloaded from
served for MRP4 and OATP2B1 in HCV-infected PXB mice compared with that in noninfected mice. In contrast, OCT1 was significantly decreased in HCV-infected PXB mice compared with that in their noninfected controls. The mRNA expression of MRP1 was below the limit of detection in both noninfected and HCV-infected groups. The mRNA levels of other ABC and SLC transporters, including P-gp, MDR3, BSEP, MRP2, MRP3, NTCP, OAT2, OATP1B1, and OATP1B3, were comparable between the two groups. mRNA Expression of Human Cytochrome P450 Enzymes. The mRNA expression of 12 human cytochrome P450 genes, CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP3A4, and CYP3A5, was investigated in the livers of noninfected and HCV-infected PXB mice (Fig. 3) . The mRNA expression of these genes was not statistically different between the two groups with the exception of significantly lower expression of CYP2D6 in HCV-infected mice.
Activity of Human Cytochrome P450 Enzymes. The activities of five major human cytochrome P450 enzymes, namely, CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, were investigated in the liver microsomes of noninfected and HCV-infected PXB mice (Fig. 4) . The metabolic activity in the liver microsomes from uPA/SCID mice for each probe substrate was comparable to or lower than that in human liver microsomes (C. Tateno, unpublished observations). Taking into account the fact that the livers of PXB mice are nearly completely (Ͼ70%) replaced with human hepatocytes, the background activity from remaining mouse hepatocyte in PXB mice is minor. The metabolic activity of CYP1A2 was significantly lower in HCV-infected PXB mice than in noninfected PXB mice. The activities of other P450s were similar between noninfected and HCV-infected PXB mice.
Discussion
In the present study, the effect of HCV infection on the mRNA expression profiles of human ABC and SLC transporters and cytochrome P450 enzymes in PXB mice was investigated. The primers and probes specific for human genes were used in the TaqMan gene expression assays to exclude the background amplification of homologous genes from the host mouse liver. In addition, we have characterized enzymatic activities of major human P450s in the microsomes isolated from the livers of PXB mice.
The body weight and human albumin concentration in the blood of PXB mice were similar between noninfected and HCV-infected groups, suggesting that the inoculation of HCV does not affect the growth of transplanted human hepatocytes inside the host mouse liver or maturation of the mice (Table 3) . A profound effect of HCV infection was observed on the status of interferon-signaling pathways, for which mRNA expression of a series of ISGs was significantly higher in the livers of HCV-infected PXB mice compared with that of noninfected controls (Fig. 1) . The up-regulation of ISGs are in good agreement with the observation in patients with chronic HCV infection and chimpanzees with acute HCV infection (Su et al., 2002; Smith et al., 2006) . In addition, these data are similar to the results published previously by Walters et al. (2006) who also used the human hepatocyte chimeric mouse model to examine the regulation of overall hepatic gene expression by HCV genotype 1a infection with microarray technology. It is of note that the effect of HCV infection on the expression of ISGs was comparable between genotype 1a (Walters et al., 2006) and 1b (this study). It is likely that there is no marked difference between the two HCV genotypes in terms of their effects on gene expression. It has been previously demonstrated that viremia in PXB mice can be reduced by treatment with IFN-␣ or pegylated-IFN as in human patients (Umehara et al., 2006; Hiraga et al., 2007; Inoue et al., 2007) . The presence of functional interferon signaling pathways in PXB mice, suggested by the up-regulation of a number of ISGs by HCV infection, provides a rationale for the efficacy of those antiviral agents in this model. These observations warrant the use of PXB mice as an in vivo model for the primary infection of the liver by HCV to investigate the effects of novel anti-HCV compounds on suppressing the replication of HCV.
There were, in general, few marked differences in the mRNA expression of human ABC and SLC transporters and cytochrome P450 enzymes in the liver between noninfected and HCV-infected PXB mice with some exceptions, e.g., significantly higher expression 
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dmd.aspetjournals.org of MRP4 and OATP2B1 and lower expression of OCT1 and CYP2D6 in HCV-infected mice than in noninfected mice (Figs. 2 and 3) . Likewise, the activities of major human cytochrome P450 enzymes were similar between noninfected and HCV-infected PXB mice except for CYP1A2, which exhibited a significantly lower activity in HCV-infected PXB mice than in noninfected mice (Fig. 4) . The effect of HCV infection on the mRNA expression and enzymatic activity of CYP1A2 and CYP2D6 was not consistent. The change in mRNA expression of CYP2D6 might not be sufficient to affect its enzymatic activity, whereas posttranscriptional effects of HCV infection may explain the decreased enzymatic activity of CYP1A2 regardless of unchanged mRNA expression. In consideration of the induction of many ISGs at the mRNA level, it is likely that the effect of HCV infection on the expression of pharmacokinetics-related genes would also be observed, if any, at the transcriptional level (CYP1A2 might be an exception). HCV infection probably affects gene expression via direct interference by virus infection, that is, the innate antiviral response and/or indirect interference by adaptive HCV-specific immune response, oxidative stress, and liver disease associated with chronic infection (Pawlotsky, 1998; Missale et al., 2004) . PXB mice are immunocompromised because of their genetic background and thus lack the adaptive immune response and liver disease associated with HCV infection: i.e., there was no hepatocyte damage or inflammation in the liver of infected chimeric mice (Hiraga et al., 2007) . HCV infection will thus affect gene expression only through the innate antiviral response in our experimental model. The similar expression profiles of drug transporters and metabolizing enzymes between noninfected and HCV-infected PXB mice suggest that innate antiviral signaling pathways play only a minor role in the regulation of mRNA expression of these genes. There have been several reports regarding the aberrant mRNA expression of drug transporters and metabolizing enzymes in patients with HCV infection compared with those without infection or healthy volunteers. Hinoshita et al. (2001) have demonstrated that the mRNA expression of P-gp, MDR3, MRP1, MRP2, and MRP3 in the noncancerous region in the liver of patients with hepatic tumor tends to be lower in HCV-infected groups than in noninfected ones. On the other hand, Ros et al. (2003) have reported increased mRNA expression of P-gp and MRP3 in the livers of patients with HCV infection compared with healthy volunteers, whereas there was no significant difference for MRP2. Nakai et al. (2001) have performed a comprehensive study of variation in the mRNA levels of drug transporters and metabolizing enzymes in patients with chronic hepatitis C using quantitative realtime PCR and observed clear correlations between fibrosis stage and mRNA levels of CYP1A2, CYP2E1, CYP3A4, NTCP, OCT1, and OATP1B1 in the liver, whereas no fibrosis stage-dependent differences were observed for other transporters and enzymes that included P-gp, MDR3, MRP1, MRP2, and MRP3 (Nakai et al., 2008) . Intriguingly, these clinical observations are inconsistent with the present findings in PXB mice in which HCV infection affects gene expression primarily through the innate antiviral response. The altered expression of drug transporters and metabolizing enzymes in clinical patients might be ascribed to the indirect interference by HCV infection or secondary effects as a result of the development of liver fibrosis or other hepatic dysfunction resulting from HCV infection. Indeed, serum levels or spontaneous productions by peripheral blood mononuclear cells of inflammatory cytokines such as tumor necrosis factor-␣, interleukin-1␤, and interleukin-6 were elevated in HCV-infected patients compared with those in healthy subjects (Kishihara et al., 1996; Huang et al., 1999; Cotler et al., 2001 ). In addition, several lines of evidence suggest perturbation of the expression of drug transporters and metabolizing enzymes by these cytokines both in vivo and in vitro (Lee and Piquette-Miller, 2003; Geier et al., 2005; Renton, 2005; Vee et al., 2009) . Oxidative stress and liver diseases including cirrhosis and hepatocellular carcinoma, which are prevalent in patients with chronic HCV infection, also compromise the physiological expression of drug transporters (Bonin et al., 2002; Toyoda et al., 2008) . This complex nature of HCV infection and progression to liver disease may account for the controversial findings regarding the expression of pharmacokinetics-related genes in clinical patients with HCV infection, although the possibility of a difference in the patient population cannot be ruled out.
Because all PXB mice used in the present study are derived from a single donor hepatocyte, future studies are necessary to generalize the present findings by characterizing different batches of PXB mice originated from other donor hepatocytes. Nevertheless, the present study has clearly demonstrated that the infection of PXB mice, the chimeric mice with humanized liver, by HCV triggers the activation of interferon-signaling pathways as observed in human patients with chronic infection, but in general does not have a significant impact on the mRNA expression profiles of human ABC and SLC transporters or on the mRNA expression and enzymatic activity of cytochrome P450 enzymes. These results suggest that the pharmacokinetic behavior of small molecule antiviral therapies such as protease and polymerase inhibitors is likely to be comparable between HCV-infected and noninfected PXB mice. The PXB mouse model is a good model to study the effects of novel anti-HCV compounds in the primary treatment of HCV infection on suppressing the replication of HCV and therefore to investigate the relationship of the pharmacokinetics and pharmacodynamics of such therapies. However, caution is needed in the translation of this relationship to HCV-infected patients because PXB mice are immunocompromised based on their genetic background (SCID), and thus this mouse model does not accurately reflect the liver disease and immune response such as the increase in the levels of inflammatory cytokines observed in patients with chronic HCV infection, which may lead to changes in drug transporter and metabolizing enzyme expression. 
CYP3A4
The gender of PXB mice did not affect the activity of human cytochrome P450 enzymes derived from the human hepatocytes inside the host mouse liver. The activity of human CYPs were determined in liver microsomes of male and female PXB mice derived from the same donor human hepatocyte (BD85) using selective substrates, CYP1A2; phenacetin (200 μM), CYP2C9; diclofenac (6 μM), CYP2C19; (S)-mephenytoin (60 μM), CYP2D6; debrisoquine (100 μM), and CYP3A4; midazolam (10 μM). The formation of each metabolite was quantified by HPLC. Results are presented as the mean ± S.D. of three mice. There was no statistically significant difference in the enzymatic activity of each CYP isoform between male and female.
